Table 7.

Neurobehavioral effects of developmental PBDE exposure

PBDE	Species	Treatment	Effect	Reference
BDE-47	NMRI mice	0.7, 10.5 mg/kg oral in el/po on PND10	Decreased habituation at 2, 4 mo. (high dose only)	Eriksson et al. 2001
BDE-47	Wistar rats	0.14, 0.7 mg/kg, oral, in po, GD6	Increased locomotor activity on PND35 and 70 (0.7 mg/kg). Decreased thigmotaxis	Kuriyama et al. 2004a
BDE-99	NMRI mice	0.2, 0.4, 12.0 mg/kg, oral, in el/po, PND10	Decreased habituation at 4 mo. (high dose only)	Viberg et al. 2004b
BDE-99	NMRI mice	8 mg/kg, oral, in el/po, PND3 or 10 or 19	Decreased habituation at 4 mo. Only if treated on PND 3 or 10	Eriksson et al. 2002
BDE-99	NMRI mice	8 mg/kg, oral, in el/po, PND10	Decreased habituation at 2 mo. Altered response to nicotine at 2 mo.	Viberg et al. 2002
BDE-99	C57/BI mice	0.4, 0.8, 4.0, 8.0, 16.0 mg/kg, oral in el/po, PND10	Decreased habituation at 2 mo at 8.0 and 16.0 mg/kg. No gender differences	Viberg et al. 2004a
BDE-99	Wistar rats	0.06, 0.3 mg/kg, oral, in po, GD6	Hyperactivity (0.3 mg/kg) on PND36, and at both doses on PND71. No effect on male sexual behavior	Kuriyama et al. 2005
BDE-99	Long Evans rats	1, 10 mg/kg, sc, in olive oil, GD10- GD18	Increased sweet preference in males on PND120 (10 mg/kg only)	Lilienthal et al. 2006
BDE-99	Long Evans rats	1, 10 mg/kg, sc in olive oil, GD10–18	Decreased sexual behavior in females	Lichtensteiger et al. 2004
BDE-99	CD-1 Swiss mice	0.6, 6.0, 30.0 mg/kg, oral, in co, GD6-PND21	Hyperactivity on PND22 and 60, not on PND120. Decreased thigmotaxis at 2 mo	Branchi et al. 2002
BDE-99	CD-1 Swiss mice	18 mg/kg, oral, in co, by self administration, GD6-PND21	Hyperactivity on PND34, not at PND60, 90, 120	Branchi et al. 2005
BDE-99	NMRI mice	0.8, 12.0 mg/kg, oral, in el/po, PND10	Decreased habituation at 2 and 4 mo at both doses. Decreased performance in Morris swim maze at 5 mo.	Eriksson et al. 2001
BDE-153	NMRI mice	0.45, 0.9, 9.0 mg/kg, oral, in el/po, PND10	Decreased habituation at 2, 4, 6 mo at the two higher doses. Effect increases with age. Decreased performance in Morris swim maze at 6 mo. (0.9 and 9.0 mg/kg)	Viberg et al. 2003a
BDE-183	NMRI mice	15.2 mg/kg, oral, el/po, PND3 or 10	Decreased habituation at 2 mo. (PND3 only)	Viberg et al. 2006
BDE-203	NMRI mice	16.8 mg/kg, oral, in el/po, PND3 or 10	Decreased habituation at 2 mo. Decreased performance in the Morris swim maze (PND10 only)	Viberg et al. 2006
BDE-206	NMRI mice	18.5 mg/kg, oral, in el/po PND3 or 10	Decreased habituation at 2 mo (PND10 only)	Viberg et al. 2006
BDE-209	NMRI mice	2.22, 20.1 mg/kg, oral, in el/po, on PND3 or 10 or 19	Decreased habituation at 2,4, 6 mo. at the high dose, only if exposed on PND3	Viberg et al. 2003b
BDE-209	Sprague Dawley rats	6.7, 20.1 mg/kg, oral, in el/po, PND3	Decreased habituation at 2 mo with both doses. Altered response to nicotine at 2 mo (high dose only)	Viberg et al. 2007a
BDE-209	C57BL6/J mice	6, 20 mg/kg, oral, in el/po, PND2–15	Developmental delay in palpebral reflex. Hyperactivity in males (20 mg/kg) at PND70, not at 1 year	Rice et al. 2007
DE-71	Long Evans rats	5, 30, 100 mg/kg, oral, in co, GD6- PND21	No effect on motor activity	MacPhail et al. 2003 (abstract)
DE-71	Rats	1, 5, 30, 100 mg/kg, oral, in co, GD6-PND21	No effect on startle reflex. Decreased fear conditioning in adult males	Taylor et al. 2003 (abstract)
DE-71	Long Evans rats	30 mg/kg, oral, in co, PND6–12	Impaired learning in a visual discrimination task on PND30–70. No effect on attention. Subsensitivity to scopolamine effect on attention	Dufault et al. 2005
DE-71	Killifish (Fundulus heteroclitus)	0.001–100 ug/L in embryos	Hyperactivity (from 0.001 dose level). Decreased predation avoidance (from 0.01 dose level)	Timme-Laragy et al. 2006

Abbreviations: co, corn oil; el/po, egg lecithin/peanut oil.